The impact of drug coverage on COX-2 inhibitor use in medicare

Health Affairs

Volumn 23, Issue SUPPL., 2004, Pages

  Doshi, Jalpa A ^a   Brandt, Nicole ^b   Stuart, Bruce ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN SYNTHASE INHIBITOR;

CARDIOVASCULAR DISEASE; COMMUNITY CARE; CORRELATION ANALYSIS; DATA ANALYSIS; DRUG MARKETING; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH SURVEY; HEARTBURN; HUMAN; INCOME; MEDICARE; NAUSEA; OSTEOARTHRITIS; OUTCOMES RESEARCH; POPULATION RESEARCH; PRESCRIPTION; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH PAIN; VOMITING; AGED; ARTICLE; ECONOMICS; FEMALE; HEALTH INSURANCE; MALE; UNITED STATES;

AGED; AGED, 80 AND OVER; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MEDICARE; UNITED STATES;

EID: 4644278612     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.W4.94     Document Type: Review

References (27)

1. Medicare Prescription Drug, Improvement, and Modernization Act of 2003, P.L. 108-173 (8 December 2003).
2. J.A. Poisal and L.A. Murray, "Growing Differences between Medicare Beneficiaries with and without Drug Coverage," Health Affairs (Mar/Apr 2001): 74-85; B. Stuart and J. Grana, "Ability to Pay and the Decision to Medicate," Medical Care 36, no. 2 (1998): 202-211; and F. Gianfrancesco, A. Baines, and D. Richards, "Utilization Effects of Prescription Drug Benefits in an Aging Population," Health Care Financing Review 15, no. 3 (1994): 113-126.
3. J.A. Poisal and L.A. Murray, "Growing Differences between Medicare Beneficiaries with and without Drug Coverage," Health Affairs (Mar/Apr 2001): 74-85; B. Stuart and J. Grana, "Ability to Pay and the Decision to Medicate," Medical Care 36, no. 2 (1998): 202-211; and F. Gianfrancesco, A. Baines, and D. Richards, "Utilization Effects of Prescription Drug Benefits in an Aging Population," Health Care Financing Review 15, no. 3 (1994): 113-126.
4. J.A. Poisal and L.A. Murray, "Growing Differences between Medicare Beneficiaries with and without Drug Coverage," Health Affairs (Mar/Apr 2001): 74-85; B. Stuart and J. Grana, "Ability to Pay and the Decision to Medicate," Medical Care 36, no. 2 (1998): 202-211; and F. Gianfrancesco, A. Baines, and D. Richards, "Utilization Effects of Prescription Drug Benefits in an Aging Population," Health Care Financing Review 15, no. 3 (1994): 113-126.
5. J. Blustein, "Drug Coverage and Drug Purchases by Medicare Beneficiaries with Hypertension," Health Affairs (Mar/Apr 2000): 219-230; A.S. Adams, S.B. Soumerai, and D. Ross-Degnan, "Use of Antihypertensive Drugs by Medicare Enrollees: Does Type of Coverage Matter?" Health Affairs (Jan/Feb 2001): 276-286; and A.D. Federman et al., "Supplemental Insurance and Use of Effective Cardiovascular Drugs among Elderly Medicare Beneficiaries with Coronary Heart Disease," Journal of the American Medical Association 286, no. 4 (2001): 1732-1739.
6. J. Blustein, "Drug Coverage and Drug Purchases by Medicare Beneficiaries with Hypertension," Health Affairs (Mar/Apr 2000): 219-230; A.S. Adams, S.B. Soumerai, and D. Ross-Degnan, "Use of Antihypertensive Drugs by Medicare Enrollees: Does Type of Coverage Matter?" Health Affairs (Jan/Feb 2001): 276-286; and A.D. Federman et al., "Supplemental Insurance and Use of Effective Cardiovascular Drugs among Elderly Medicare Beneficiaries with Coronary Heart Disease," Journal of the American Medical Association 286, no. 4 (2001): 1732-1739.
7. J. Blustein, "Drug Coverage and Drug Purchases by Medicare Beneficiaries with Hypertension," Health Affairs (Mar/Apr 2000): 219-230; A.S. Adams, S.B. Soumerai, and D. Ross-Degnan, "Use of Antihypertensive Drugs by Medicare Enrollees: Does Type of Coverage Matter?" Health Affairs (Jan/Feb 2001): 276-286; and A.D. Federman et al., "Supplemental Insurance and Use of Effective Cardiovascular Drugs among Elderly Medicare Beneficiaries with Coronary Heart Disease," Journal of the American Medical Association 286, no. 4 (2001): 1732-1739.
8. A.C. Nyquist et al., "Antibiotic Prescribing for Children with Colds, Upper Respiratory Tract Infections, and Bronchitis," Journal of the American Medical Association 279, no. 11 (1998): 875-877; and M.A. Steinman, C.S. Landefeld, and R. Gonzales, "Predictors of Broad-Spectrum Antibiotic Prescribing for Acute Respiratory Tract Infections in Adult Primary Care," Journal of the American Medical Association 289, no. 6 (2003): 719-725.
9. A.C. Nyquist et al., "Antibiotic Prescribing for Children with Colds, Upper Respiratory Tract Infections, and Bronchitis," Journal of the American Medical Association 279, no. 11 (1998): 875-877; and M.A. Steinman, C.S. Landefeld, and R. Gonzales, "Predictors of Broad-Spectrum Antibiotic Prescribing for Acute Respiratory Tract Infections in Adult Primary Care," Journal of the American Medical Association 289, no. 6 (2003): 719-725.
10. R.C. Lawrence et al., "Estimates of the Prevalence of Arthritis and Selected Musculoskeletal Disorders in the United States," Arthritis and Rheumatism 41, no. 5 (1998): 778-799; and S.L. Hughes and D. Dunlop, "The Prevalence and Impact of Arthritis in Older Persons," Arthritis Care Research 8, no. 4 (1995): 257-264.
11. R.C. Lawrence et al., "Estimates of the Prevalence of Arthritis and Selected Musculoskeletal Disorders in the United States," Arthritis and Rheumatism 41, no. 5 (1998): 778-799; and S.L. Hughes and D. Dunlop, "The Prevalence and Impact of Arthritis in Older Persons," Arthritis Care Research 8, no. 4 (1995): 257-264.
12. G. Singh and D.R. Ramey, "NSAID-Induced Gastrointestinal Complications: The ARAMIS Perspective - 1997," Journal of Rheumatology 25, Supp. 51 (1998): 8-16; and G. Singh and G. Triadafilopoulus, "Epidemiology of NSAID-Induced GI Complications," Journal of Rheumatology 26, Supp. 56 (1999): 18-24.
13. G. Singh and D.R. Ramey, "NSAID-Induced Gastrointestinal Complications: The ARAMIS Perspective - 1997," Journal of Rheumatology 25, Supp. 51 (1998): 8-16; and G. Singh and G. Triadafilopoulus, "Epidemiology of NSAID-Induced GI Complications," Journal of Rheumatology 26, Supp. 56 (1999): 18-24.
14. F.E. Silverstein et al., "Gastrointestinal Toxicity with Celecoxib versus Nonsteroidal Anti-Inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis, The CLASS Study: A Randomized Controlled Trial," Journal of the American Medical Association 284, no. 10 (2000): 1247-1255; and C. Bombardier et al., "Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis: VIGOR Study Group," New England Journal of Medicine 343, no. 21 (2000): 1520-1528.
15. F.E. Silverstein et al., "Gastrointestinal Toxicity with Celecoxib versus Nonsteroidal Anti-Inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis, The CLASS Study: A Randomized Controlled Trial," Journal of the American Medical Association 284, no. 10 (2000): 1247-1255; and C. Bombardier et al., "Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis: VIGOR Study Group," New England Journal of Medicine 343, no. 21 (2000): 1520-1528.
16. I b i d.
17. B.M. Spiegel et al., "The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis," Annals of Internal Medicine 138, no. 10 (2003): 795-806; and A. Maetzel, M. Krahn, and G. Naglie, "The Cost Effectiveness of Rofecoxib and Celecoxib in Patients with Osteoarthritis or Rheumatoid Arthritis," Arthritis and Rheumatism 49, no. 3 (2003): 283-292.
18. B.M. Spiegel et al., "The Cost-Effectiveness of Cyclooxygenase-2 Selective Inhibitors in the Management of Chronic Arthritis," Annals of Internal Medicine 138, no. 10 (2003): 795-806; and A. Maetzel, M. Krahn, and G. Naglie, "The Cost Effectiveness of Rofecoxib and Celecoxib in Patients with Osteoarthritis or Rheumatoid Arthritis," Arthritis and Rheumatism 49, no. 3 (2003): 283-292.
19. D. Mukherjee, S.E. Nissen, and E.J. Topol, "Risk Of Cardiovascular Events Associated with Selective COX-2 Inhibitors," Journal of the American Medical Association 286, no. 8 (2001): 954-959; and S.L. Targum, U.S. Food and Drug Administration, "Memorandum: Review of Cardiovascular Safety Database," 1 February 2001, www.fda.gov/ohrms/dockets/ac/01/briefing/ 3677b2_06_cardio.pdf (14 January 2004).
20. D. Mukherjee, S.E. Nissen, and E.J. Topol, "Risk Of Cardiovascular Events Associated with Selective COX-2 Inhibitors," Journal of the American Medical Association 286, no. 8 (2001): 954-959; and S.L. Targum, U.S. Food and Drug Administration, "Memorandum: Review of Cardiovascular Safety Database," 1 February 2001, www.fda.gov/ohrms/dockets/ac/01/briefing/ 3677b2_06_cardio.pdf (14 January 2004).
21. Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel, Veterans Health Adminstration, Department of Veterans Affairs, "Use of Cyclooxygenase (COX) 2 Inhibitors Celecoxib (Celebrex) or Rofecoxib (Vioxx) in Veterans," April 2001, www.vapbm.org/criteria/coxcriteria.pdf (3 February 2004); G. Singh et al., "GI Score: A Simple Self-Assessment Instrument to Quantify the Risk of Serious NSAID-Related GI Complications in RA and OA" (abstract), Arthritis and Rheumatism 41, Supp. (1998): S75; and M.M. Wolfe, D.R. Lichtenstein, and G. Singh, "Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs," New England Journal of Medicine 340, no. 24 (1999): 1888-1899.
22. Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel, Veterans Health Adminstration, Department of Veterans Affairs, "Use of Cyclooxygenase (COX) 2 Inhibitors Celecoxib (Celebrex) or Rofecoxib (Vioxx) in Veterans," April 2001, www.vapbm.org/criteria/coxcriteria.pdf (3 February 2004); G. Singh et al., "GI Score: A Simple Self-Assessment Instrument to Quantify the Risk of Serious NSAID-Related GI Complications in RA and OA" (abstract), Arthritis and Rheumatism 41, Supp. (1998): S75; and M.M. Wolfe, D.R. Lichtenstein, and G. Singh, "Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs," New England Journal of Medicine 340, no. 24 (1999): 1888-1899.
23. Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel, Veterans Health Adminstration, Department of Veterans Affairs, "Use of Cyclooxygenase (COX) 2 Inhibitors Celecoxib (Celebrex) or Rofecoxib (Vioxx) in Veterans," April 2001, www.vapbm.org/criteria/coxcriteria.pdf (3 February 2004); G. Singh et al., "GI Score: A Simple Self-Assessment Instrument to Quantify the Risk of Serious NSAID-Related GI Complications in RA and OA" (abstract), Arthritis and Rheumatism 41, Supp. (1998): S75; and M.M. Wolfe, D.R. Lichtenstein, and G. Singh, "Gastrointestinal Toxicity of Nonsteroidal Antiinflammatory Drugs," New England Journal of Medicine 340, no. 24 (1999): 1888-1899.
24. Singh et al., "GI Score."
25. Adams et al., "Use of Antihypertensive Drugs by Medicare Enrollees"; and Federman et al., "Supplemental Insurance and Use of Effective Cardiovascular Drugs."
26. Adams et al., "Use of Antihypertensive Drugs by Medicare Enrollees"; and Federman et al., "Supplemental Insurance and Use of Effective Cardiovascular Drugs."
27. Reestimation of the logistic regression with the individual GI risk factors (see Exhibit 4) instead of the GI risk score categories resulted in similar adjusted-odds ratios for the generosity-of-coverage categories.